logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12378260 B1

PDFFull Text
Date of Patent:
Aug. 05, 2025

Filed:

Oct. 25, 2024

Benzotriazole compound

Applicants:

Daiichi Sankyo Company, Limited, Tokyo, JP;

Kyoto Pharmaceutical Industries, Ltd., Kyoto, JP;

Inventors:

Yoshihiro Ogura, Tokyo, JP;

Rieko Takano, Tokyo, JP;

Junya Kawai, Tokyo, JP;

Teppei Fujimoto, Tokyo, JP;

Masaharu Inui, Tokyo, JP;

Masafumi Ofuku, Tokyo, JP;

Masaki Miyazaki, Tokyo, JP;

Masaya Fujii, Tokyo, JP;

Ken Ishii, Tokyo, JP;

Wakana Yokozeki, Tokyo, JP;

Kazuya Otake, Kyoto, JP;

Shunsuke Takashima, Kyoto, JP;

Masafumi Ando, Kyoto, JP;

Assignees:

DAIICHI SANKYO COMPANY, LIMITED, Tokyo, JP;

KYOTO PHARMACEUTICAL INDUSTRIES, LTD., Kyoto, JP;

Attorney:

Christensen O'Connor Johnson Kindness PLLC

Primary Examiner:

Bruck Kifle

Int. Cl.
CPC ...
C07D 409/06 (2006.01); A61K 31/4192 (2006.01); A61K 31/4353 (2006.01); A61K 31/553 (2006.01); A61K 31/554 (2006.01); C07D 417/10 (2006.01); C07D 419/10 (2006.01); C07D 419/14 (2006.01); C07D 491/10 (2006.01); C07D 491/14 (2006.01); C07D 498/04 (2006.01); C07D 513/04 (2006.01); C07D 515/04 (2006.01); C07D 515/20 (2006.01); C07D 519/00 (2006.01);
U.S. Cl.
CPC ...
C07D 515/04 (2013.01); A61K 31/554 (2013.01); C07D 417/10 (2013.01); C07D 419/10 (2013.01); C07D 419/14 (2013.01); C07D 513/04 (2013.01); C07D 515/20 (2013.01); C07D 519/00 (2013.01);
Abstract

The present invention aims to provide a medicament capable of treating and/or preventing diseases associated with oxidative stress by inhibiting the protein-protein interaction between Keap1 and Nrf2 and activating Nrf2. The present invention relates to a compound represented by the following formula (1): wherein each symbol is as described in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. In addition, the present invention also relates to a medicament containing the aforementioned compound, for the prophylaxis and/or treatment of diseases involving oxidative stress selected from the group consisting of chronic kidney disease, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, radiation skin disorder, radiation mucosal disorder, cardiac failure, pulmonary arterial hypertension, Parkinson's disease, Friedreich's ataxia, multiple sclerosis, age-related macular degeneration, retinitis pigmentosa and glaucoma.

Find Patent Forward Citations

Loading…